Calidi Biotherapeutics Signs Material Definitive Agreement
Ticker: CLDWW · Form: 8-K · Filed: Aug 22, 2025 · CIK: 1855485
| Field | Detail |
|---|---|
| Company | Calidi Biotherapeutics, Inc. (CLDWW) |
| Form Type | 8-K |
| Filed Date | Aug 22, 2025 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001, $6.9 m, $3, $2.00, $1.999 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, corporate-event
TL;DR
Calidi Biotherapeutics just signed a big deal, filing an 8-K on 8/20/25.
AI Summary
On August 20, 2025, Calidi Biotherapeutics, Inc. entered into a material definitive agreement. The company, formerly known as First Light Acquisition Group, Inc., is incorporated in Delaware and headquartered in San Diego, California.
Why It Matters
This filing indicates a significant new contract or partnership for Calidi Biotherapeutics, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — Entering into material definitive agreements can introduce new risks related to contract performance, financial obligations, or strategic alignment.
Key Players & Entities
- Calidi Biotherapeutics, Inc. (company) — Registrant
- August 20, 2025 (date) — Date of earliest event reported
- First Light Acquisition Group, Inc. (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
- San Diego, California (location) — Principal executive offices
FAQ
What is the nature of the material definitive agreement entered into by Calidi Biotherapeutics?
The filing states that Calidi Biotherapeutics, Inc. entered into a material definitive agreement on August 20, 2025, but the specific details of the agreement are not provided in this excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on August 20, 2025.
What was Calidi Biotherapeutics, Inc. previously known as?
Calidi Biotherapeutics, Inc. was formerly known as First Light Acquisition Group, Inc.
In which state is Calidi Biotherapeutics, Inc. incorporated?
Calidi Biotherapeutics, Inc. is incorporated in Delaware.
What is the business address of Calidi Biotherapeutics, Inc.?
The business address of Calidi Biotherapeutics, Inc. is 4475 Executive Drive, Suite 200, San Diego, California 92121.
Filing Stats: 1,521 words · 6 min read · ~5 pages · Grade level 10.7 · Accepted 2025-08-22 17:27:23
Key Financial Figures
- $0.0001 — ch Registered Common stock, par value $0.0001 per share CLDI NYSE American LLC
- $6.9 m — ting in gross proceeds of approximately $6.9 million, before deducting underwriting di
- $3 — ve's Warrants have an exercise price of $3.00, are immediately exercisable and wil
- $2.00 — it was sold to the public at a price of $2.00 per Common Stock Unit and each Pre-Fund
- $1.999 — it was sold to the public at a price of $1.999 per Pre-Funded Unit (which represents t
- $0.001 — rice of each Common Stock Unit less the $0.001 per share nominal exercise price for ea
Filing Documents
- form8-k.htm (8-K) — 50KB
- ex99-1.htm (EX-99.1) — 16KB
- ex99-2.htm (EX-99.2) — 15KB
- ex99-1_001.jpg (GRAPHIC) — 7KB
- ex99-2_001.jpg (GRAPHIC) — 7KB
- 0001641172-25-025273.txt ( ) — 277KB
- cldi-20250820.xsd (EX-101.SCH) — 3KB
- cldi-20250820_lab.xml (EX-101.LAB) — 33KB
- cldi-20250820_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 1.1 Underwriting Agreement, dated August 20, 2025 (incorporated herein by reference to Exhibit 1.1 to Form S-1 filed with the SEC on August 15, 2025) . 4.1 Form of Pre-funded Warrant (incorporated herein by reference to Exhibit 4.21 to Form S-1 filed with the SEC on August 15, 2025). 4.2 Form of Series I Common Warrant (incorporated herein by reference to Exhibit 4.20 to Form S-1 filed with the SEC on August 15, 2025). 4.3 Form of Representative Warrant (incorporated herein by reference to Exhibit 4.22 to Form S-1 filed with the SEC on August 15, 2025). 10.1 Form of Warrant Agency Agreement (incorporated herein by reference to Exhibit 4.23 to Form S-1 filed with the SEC on August 15, 2025). 99.1 Pricing Press Release dated August 20, 2025. 99.2 Closing Press Release dated August 21, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CALIDI BIOTHERAPEUTICS, INC. Dated: August 22, 2025 By: /s/ Andrew Jackson Name: Andrew Jackson Title: Chief Financial Officer